Number 3: Sarfaraz K. Niazi, PhD, asserts that India's recently revised 2025 biosimilar guidelines represent a significant and rational step towards global regulatory alignment by deemphasizing animal ...

Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the ...

Eculizumab biosimilars could provide European patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic ...

In conclusion, the 2025 CDSCO draft guidelines represent a meaningful and commendable step toward global regulatory alignment ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...